PharmaEssentia

PharmaEssentia's 2024 annual report says its U.S. subsidiary continued to extend the drug's reach through AI technologies, together with social media, advocacy groups, clinic information displays and dedicated websites.

The PharmaEssentia Innovation Research Center site says its data science team uses an extensive database and employs AI and ML to select checkpoint-receptor targets. The same page says the center uses AI and machine learning to establish databases so it can select novel targets and patients more wisely and screen molecules faster.

PharmaEssentia USA, announcing abstracts for the MPN Congress and ASH, said the program included an AI-based discovery analysis and listed a presentation described as a causal-AI dissection of RNA-seq data sets that pinpoints connections between myeloproliferative neoplasms and neurodegenerative diseases.

PharmaEssentia announced the PharmaEssentia Innovation Research Center in the Boston area and said data scientists at the center will use artificial intelligence and machine learning to inform new target and indication selections.